MedTrace Logo

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

NCT05544968 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-04-03

No results posted yet for this study

Summary

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

Conditions

  • Hodgkin Disease
  • CD30-Positive Diffuse Large B-Cell Lymphoma
  • CD30+ Anaplastic Large Cell Lymphoma
  • CD30+ Pleomorphic Large T-Cell Cutaneous Lymphoma
  • CD30+ Immunoblastic Large T-Cell Cutaneous Lymphoma
  • Leukemia
  • Lymphoma

Interventions

DRUG

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells

DRUG

GM-CSF

Hematopoietic agent that helps form white blood cells.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Guru Subramanian Guru Murthy, MD, MS · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2028-01-31
Completion
2029-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05544968 on ClinicalTrials.gov